The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder?
Abstract
Altered protein handling is thought to play a key role in the etiopathogenesis of Parkinson's disease (PD), as the disorder is characterized neuropathologically by the accumulation of intraneuronal protein aggregates (Lewy bodies and Lewy neurites). Attention has particularly focused on the α‐synuclein protein, as it is the principal component of Lewy pathology. Moreover, point mutations in the α‐synuclein gene cause rare familial forms of PD. Importantly, duplication/triplication of the wild type α‐synuclein gene also cause a form of PD, indicating that increased levels of the normal α‐synuclein protein is sufficient to cause the disease. Further, single nucleotide polymorphisms in the α‐synuclein gene are associated with an increased risk of developing sporadic PD. Recent evidence now suggests the possibility that α‐synuclein is a prion‐like protein and that PD is a prion‐like disease. Within cells, α‐synuclein normally adopts an α‐helical conformation. However, under certain circumstances, the protein can undergo a profound conformational transition to a β‐sheet–rich structure that polymerizes to form toxic oligomers and amyloid plaques. Recent autopsy studies of patients with advanced PD who received transplantation of fetal nigral mesencephalic cells more than a decade earlier demonstrated that typical Lewy pathology had developed within grafted neurons. This suggests that α‐synuclein in an aberrantly folded, β‐sheet–rich form had migrated from affected to unaffected neurons. Laboratory studies confirm that α‐synuclein can transfer from affected to unaffected nerve cells, where it appears that the misfolded protein can act as a template to promote misfolding of host α‐synuclein. This leads to the formation of larger aggregates, neuronal dysfunction, and neurodegeneration. Indeed, recent reports demonstrate that a single intracerebral inoculation of misfolded α‐synuclein can induce Lewy‐like pathology in cells that can spread from affected to unaffected regions and can induce neurodegeneration with motor disturbances in both transgenic and normal mice. Further, inoculates derived from the brains of elderly α‐synuclein–overexpressing transgenic mice have now been shown to accelerate the disease process when injected into the brains of young transgenic animals. Collectively, these findings support the hypothesis that α‐synuclein is a prion‐like protein that can adopt a self‐propagating conformation that causes neurodegeneration. We propose that this mechanism plays an important role in the development of PD and provides novel targets for candidate neuroprotective therapies. © 2013 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“stage of the disease; and affecting the cerebral hemispheres in the later stages of the illness.(18) While this”
BackgroundSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Self-citationMasliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Cited by
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3549 · Cited by 869
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“Importantly, the prion hypothesis identifies a series of novel targets and candidate therapeutic interventions that might prevent the formation or facilitate the clearance of misfolded alpha-synuclein and thereby have disease-modifying effects.(268,269)”
Self-citationAmyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628
“Oligomers were found to migrate from affected to unaffected neurons, where it was suggested they act as a template to promote formation of larger oligomers in a self-propagating manner [133].”
BackgroundBrain-Gut-Microbiota Axis in Parkinson’s Disease
Mulak, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10609 · Cited by 583
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
Regulation of autophagy by the Rab GTPase network
Ao, X., Zou, L., & Wu, Y. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.187 · Cited by 411
Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathology
Del Tredici, K., & Braak, H. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12298 · Cited by 398
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bezard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 392
Self-citationBraak, H., & Del Tredici, K. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179001 · Cited by 372
Vagal neurocircuitry and its influence on gastric motility
Travagli, R. A., & Anselmi, L. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.76 · Cited by 323
Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases
Lee, H.-J., Bae, E.-J., & Lee, S.-J. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.275 · Cited by 306
Marotta, N. P., Lin, Y. H., Lewis, Y. E., Ambroso, M. R., Zaro, B. W., Roth, M. T., Arnold, D. B., Langen, R., & Pratt, M. R. (2015) · Nature Chemistry · doi:10.1038/nchem.2361 · Cited by 301
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
Espay, A. J., Vizcarra, J. A., Marsili, L., Lang, A. E., Simon, D. K., Merola, A., Josephs, K. A., Fasano, A., Morgante, F., Savica, R., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000006926 · Cited by 274
Self-citationInflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
Copper and Copper Proteins in Parkinson’s Disease
Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., & Rios, C. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/147251 · Cited by 203
The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Rui, Q., Ni, H., Li, D., Gao, R., & Chen, G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180222165418 · Cited by 196
iPS cell-based therapy for Parkinson's disease: A Kyoto trial
Takahashi, J. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.06.002 · Cited by 192
Neuropathology of multiple system atrophy: New thoughts about pathogenesis
Jellinger, K. A. (2014) · Movement Disorders · doi:10.1002/mds.26052 · Cited by 181
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance
Travagli, R. A., Browning, K. N., & Camilleri, M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0339-z · Cited by 181
Price, D. L., Koike, M. A., Khan, A., Wrasidlo, W., Rockenstein, E., Masliah, E., & Bonhaus, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-34490-9 · Cited by 165
Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases
D’Anca, M., Fenoglio, C., Serpente, M., Arosio, B., Cesari, M., Scarpini, E. A., & Galimberti, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00232 · Cited by 154
The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease
Baizabal-Carvallo, J. F., & Alonso-Juarez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.030 · Cited by 130
Iba, M., Kim, C., Sallin, M., Kwon, S., Verma, A., Overk, C., Rissman, R. A., Sen, R., Sen, J. M., & Masliah, E. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01888-0 · Cited by 120
RetractedOlanow, C. W., Savolainen, M., Chu, Y., Halliday, G. M., & Kordower, J. H. (2019) · Brain · doi:10.1093/brain/awz104 · Cited by 112
Self-citationRivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
Gut Microbiota-Derived Metabolite Trimethylamine N-Oxide as a Biomarker in Early Parkinson’s Disease
Chung, S. J., Rim, J. H., Ji, D., Lee, S., Yoo, H. S., Jung, J. H., Baik, K., Choi, Y., Ye, B. S., Sohn, Y. H., et al. (2021) · Nutrition · doi:10.1016/j.nut.2020.111090 · Cited by 74
Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia
Maekawa, T., Sasaoka, T., Azuma, S., Ichikawa, T., Melrose, H. L., Farrer, M. J., & Obata, F. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0315-2 · Cited by 59
Valera, E., Spencer, B., Mott, J., Trejo, M., Adame, A., Mante, M., Rockenstein, E., Troncoso, J. C., Beach, T. G., Masliah, E., et al. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00329 · Cited by 55
“MicroRNA qPCR was performed using TaqMan Universal Master Mix II, no UNG and speciesspecific TaqMan miRNA primers, using U6 as internal control (Peltier and Latham, 2008). qPCR reactions were run in an StepOnePlus Real-Time PCR system (Applied Biosystems) and ∆∆Ct calculations were made using…”
MethodGenetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
Wu, Z., Xia, Y., Wang, Z., Su Kang, S., Lei, K., Liu, X., Jin, L., Wang, X., Cheng, L., & Ye, K. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0687-7 · Cited by 41
Post-COVID-19 Parkinsonism and Parkinson’s Disease Pathogenesis: The Exosomal Cargo Hypothesis
Mysiris, D. S., Vavougios, G. D., Karamichali, E., Papoutsopoulou, S., Stavrou, V. T., Papayianni, E., Boutlas, S., Mavridis, T., Foka, P., Zarogiannis, S. G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179739 · Cited by 25
Hippocampal proliferation is increased in presymptomatic Parkinson’s disease and due to microglia
Doorn, K. J., Drukarch, B., van Dam, A.-M., & Lucassen, P. J. (2014) · Neural Plasticity · doi:10.1155/2014/959154 · Cited by 24
Berrío Sánchez, J., Cucarian Hurtado, J., Barcos Nunes, R., & de Oliveira, A. A. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0011 · Cited by 7
Stem Cells, Derived Exosomes, and Associated Signaling Molecules in Neuroprotection
Jahan, S., Kumar, D., Mukherjee, S., Roy, K., Siddiqui, A. J., Khan, A., Rajpurohit, C. S., & Aldosari, S. (2023) · Applications of Stem Cells and derived Exosomes in Neurodegenerative Disorders · doi:10.1007/978-981-99-3848-3_11 · Cited by 3
Metadata
- Authors
- Olanow, C. W., & Brundin, P.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2013-01
- Volume
- 28
- Issue
- 1
- Pages
- 31-40
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1851334881
- Cited by
- 390
- References
- 69
- FWCI
- 24.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.